Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer (LANCET): A Multicenter, Single-arm, Phase II Trial

Next Previous
X
Search
Trial Profile

Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer (LANCET): A Multicenter, Single-arm, Phase II Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin
  • Indications Advanced breast cancer; Carcinoma; Early breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms LANCET

    • Most Recent Events

    • 07 Jun 2022 Results (data cutoff date: 31 Dec 2021) reporting efficacy and toxicities presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 29 Jan 2022 Status changed from not yet recruiting to completed.
    • 03 Feb 2018 Trial design, arms and interventions has been amended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top